Biotechnology

Oragenics

Oragenics released FY2026 Q1 earnings on May 8 (EST), actual revenue USD 0, actual EPS USD -0.5118

Oragenics released FY2025 Q4 earnings on March 16 (EST), actual revenue USD 0, actual EPS USD -0.54

Oragenics released FY2025 Annual Earnings on March 16 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.5628 (forecast USD -0.76)

Oragenics released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 0, actual EPS USD -1.9646

Oragenics released FY2025 9 Months Earnings on November 7 (EST), actual revenue USD 0, actual EPS USD -8.7207

Oragenics Collaborates with Receptor.AI to Accelerate Drug Development

Oragenics released FY2025 Q2 earnings on August 8 (EST) with actual revenue of USD 0 and EPS of USD -3.1046

Oragenics released FY2025 Semi-Annual earnings on August 8 (EST) with actual revenue of USD 0 and EPS of USD -6.6229

Oragenics Signs Manufacturing Agreement with Sterling

Oragenics Announces Offering of Convertible Preferred Stock to Raise Funds

Odyssey Health Disposes of Oragenics Inc. Shares

Oragenics Submits Beneficial Ownership Statement with Odyssey Health Holding 10%

Wall Street Zen Analysts Assigns Oragenics a Sell Rating

Oragenics released FY2025 Q1 earnings on May 9, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.6514

Oragenics, Inc. Submits Clinical Trial Protocol for Review

Oragenics Inc Submits Application to Health and Disability Ethics Committee for Phase II Concussion Trial

Oragenics released FY2024 annual earnings on March 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -47.8769 (forecast USD 360.0359)

Oragenics released FY2024 Q4 earnings on March 14 (EST), actual revenue USD 0, actual EPS USD -5.0039

Oragenics released FY2024 9 Months Earnings on November 13 (EST) with actual revenue of USD 0 and EPS of USD -47.6209

Oragenics released FY2024 Q3 earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -11.3182

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

OGEN

ARKG

LABU

SBIO

Oragenics has initiated Phase IIa dosing of ONP-002 in Australia, with a cash balance of $6.1M and a Letter of Intent for a CNS device. The trial involves 40 patients and focuses on safety and feasibility, with no serious adverse events reported. The company plans to request an FDA Type C meeting in Q2 2026 and aims for a full IND submission by the end of 2026. R&D expenses have increased by 89% to $0.6M, and an annual meeting is scheduled for June 29, 2026.

TradingView

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VG Health

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Health Care Select Sector SPDR

Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device

Earnings Watch

Oragenics | 10-Q: FY2026 Q1 Revenue: USD 0

Oragenics Inc. has initiated the Phase 2a trial for ONP-002, its lead candidate for treating concussions and mild traumatic brain injury (mTBI). This investigational neurosteroid aims to reduce neuroinflammation and oxidative stress. The trial will involve 40 patients and assess safety and tolerability. An IND application is expected by Q4 2026. OGEN's stock closed at $0.68, up 12.95%.

nasdaq

iShares Global Healthcare

Nasdaq

Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News

StockTitan

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News

Oragenics(OGEN.US)

Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device

Oragenics | 10-Q: FY2026 Q1 Revenue: USD 0

Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News